25 October 2022 in Journal of Bone and Joint Surgery
Background: There is currently no ideal treatment for osteochondral lesions of the femoral head (OLFH) in young patients. Methods: We performed a 1-year single-arm study and 2 additional years of follow-up of patients with a large (defined as >3 cm2) OLFH treated with insertion of autologous costal cartilage graft (ACCG) to restore femoral head congruity after lesion debridement. Twenty patients ≤40 years old who had substantial hip pain and/or dysfunction after nonoperative treatment were enrolled at a single center. The primary outcome was the change in Harris hip score (HHS) from baseline to 12 months postoperatively. Secondary outcomes included the EuroQol visual analogue scale (EQ VAS), hip joint space width, subchondral integrity on computed tomography scanning, repair tissue status evaluated with the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score, and evaluation of cartilage biochemistry by delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC) and T2 mapping. Results: All 20 enrolled patients (31.02 ± 7.19 years old, 8 female and 12 male) completed the initial study and the 2 years of additional follow-up. The HHS improved from 61.89 ± 6.47 at baseline to 89.23 ± 2.62 at 12 months and 94.79 ± 2.72 at 36 months. The EQ VAS increased by 17.00 ± 8.77 at 12 months and by 21.70 ± 7.99 at 36 months (p < 0.001 for both). Complete integration of the ACCG with the bone was observed by 12 months in all 20 patients. The median MOCART score was 85 (interquartile range [IQR], 75 to 95) at 12 months and 75 (IQR, 65 to 85) at the last follow-up (range, 24 to 38 months). The ACCG demonstrated magnetic resonance properties very similar to hyaline cartilage; the median ratio between the relaxation times of the ACCG and recipient cartilage was 0.95 (IQR, 0.90 to 0.99) at 12 months and 0.97 (IQR, 0.92 to 1.00) at the last follow-up. Conclusions: ACCG is a feasible method for improving hip function and quality of life for at least 3 years in young patients who were unsatisfied with nonoperative treatment of an OLFH. Promising long-term outcomes may be possible because of the good integration between the recipient femoral head and the implanted ACCG. Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
14 July 2021 in Advanced Healthcare Materials
1 October 2022 in JBJS Case Connector
Case: We describe a patient with advanced Kienböck's disease, treated with 3-dimensional (3D) printing assisted costochondral transplantation. Cartilage shaping was achieved according to a biomimetic 3D-printed prosthesis designed by mirror symmetry of the healthy wrist. The inserted cartilage spacer was fixed using the autologous palmar longus tendon. After 14 months of follow-up, the patient had significant pain relief and had recovered nearly the full range of wrist motion. No significant absorption or osseous metaplasia of the cartilage was seen on the radiographic and magnetic resonance images. Conclusion: This costochondral transplantation strategy may offer a feasible treatment option for patients with severe Kienböck's disease.
1 April 2026 in JBJS Open Access
Background: Osteochondral lesions of the talus (OLT) are common and clinically challenging conditions with no consensus on how to optimally treat them. This prospective single-arm study aimed to evaluate the clinical outcomes of autologous costal cartilage transplantation (ACCT) for OLT. Methods: A prospective single-arm study of patients who were diagnosed with medial OLT and underwent ACCT with 2 years of follow-up was performed. There were 28 patients enrolled at a single center. The primary outcome was changes in American Orthopaedic Foot and Ankle Society (AOFAS) scores from baseline. The secondary outcomes included results of the EuroQol 5-dimension 5-level questionnaire (EQ-5D-5L) for quality of life, the visual analog scale for pain, the Tegner score for sports activity, and magnetic resonance observation of cartilage repair tissue (MOCART) scoring system for imaging evaluations. Results: All 28 enrolled patients (41.82 ± 11.98 years, 9 female and 19 male) completed the initial study and the 2 years of follow-up. The AOFAS score improved significantly from 58.89 ± 8.74 preoperatively to 86.5 ± 7.41 at 1 year and 90.53 ± 5.49 at 2 years (p < 0.01 for both). EQ-5D-5L index improved from 0.866 ± 0.042 at baseline to 0.976 ± 0.041 at 2 years postoperatively (p < 0.01). Tegner score increased by 1.96 ± 0.69 at 2 years (p < 0.01). Patients reported significant pain relief at 2 years postoperatively (VAS: from 3.89 ± 0.87 to 0.75 ± 0.58, p < 0.01; EQ VAS: from 63.75 ± 6.02 to 88.57 ± 6.21, p < 0.01). The mean MOCART scores were 81.07 ± 11.25 at 6 months, 83.57 ± 11.85 at 1 year, and 82.32 ± 10.92 at 2 years. Complete filling of the defect was observed in all 28 patients at 2 years, and complete integration of the graft with the bone was seen in 25 cases (89.29%). Conclusions: ACCT for OLT led to significant improvement in clinical outcomes and effectively repaired talar osteochondral lesions, with grafts maintaining stability and integrating well with the host tissue over time. This study introduces ACCT as a novel strategy for OLT. Level of evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.